InnoCare Pharma (09969) released its first quarter performance, with a net profit attributable to shareholders of 106 million yuan, a year-on-year increase of 488.93%.

InnoCare Pharma (09969) released the first quarter report of 2026, with the group achieving operating revenue of 529 million yuan, a year-on-year increase of 38.65%; net profit attributable to shareholders of the listed company was 106 million yuan, a year-on-year increase of 488.93%; basic earnings per share were 0.06 yuan. In the first quarter of 2026, the company's drug sales revenue was 450 million yuan, an increase of 44.54% compared to the same period last year, with total operating revenue of 529 million yuan, an increase of 38.65% compared to the same period last year. The main reasons for the increase in operating revenue were the continuous growth of core product Orelotinib, the additional contributions of Tanxetinib monoclonal antibody and Zalotinib, and the completion of milestone deliveries after the authorization and licensing agreement with Zenas BioPharma, Inc. ("Zenas"). The company's net profit in the first quarter of 2026 was 102 million yuan, an increase of 607.72% compared to the same period last year. The company's commercialization system is mature, the research pipeline is progressing smoothly, and high-quality growth will be maintained in the future. As of March 31, 2026, the company holds a cash and related account balance of approximately 7.921 billion yuan, composed of cash balance, financial assets recorded in trading financial assets, other current assets, financial assets due within one year, and other non-current assets.